Refer to the following safety details for the prescription treatments offered through Ozari. This information is not comprehensive and is not a substitute for the advice of your healthcare provider. Report side effects to a licensed healthcare provider and to the pharmacy that dispensed your medication. To report suspected reactions, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch. If you are experiencing a medical emergency, call 911.
Ozari LLC, which operates as Ozari Health, connects users with independent, licensed healthcare providers and coordinates fulfillment through licensed pharmacies. Ozari does not provide medical advice, dispense medication, or operate as a licensed healthcare facility or pharmacy.
Advertisements for Ozari are paid for by Ozari LLC. Some advertisements may feature paid actors, dramatizations, or AI-generated presenters; where an advertisement features a real Ozari customer or endorsement, that is clearly disclosed. AI-generated presenters do not depict a real customer and do not describe personal experience with any product. Where an advertisement shows a result, it also states the generally expected result. Individual results vary.
Prescription drugs require evaluation and approval by a licensed provider and are issued solely at the provider's discretion. Access is not guaranteed. In certain cases, providers may prescribe compounded medications, which are custom-prepared by licensed U.S. compounding pharmacies for an individual patient based on a documented, patient-specific clinical determination. Compounded drugs are not FDA-approved and do not undergo FDA review for safety or effectiveness. FDA-approved alternatives may be available. Ozari does not compound or manufacture medications.
Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozari is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and compounded tirzepatide are not the same as these brand-name products.
Semaglutide is the active ingredient in the FDA-approved products Ozempic and Wegovy. Compounded semaglutide is not FDA-approved and has not undergone the clinical studies required for FDA-approved products. The FDA-approved brand products carry a boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC); the same risk should be assumed for compounded semaglutide. Do not use if you or a family member has had MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to semaglutide.
Before use, tell your provider about all medical conditions and all medicines you take. Possible serious risks include pancreatitis, gallbladder problems, kidney problems, serious allergic reactions, low blood sugar, vision changes, gastroparesis (stomach paralysis), and depression or thoughts of suicide. There is a risk of retained stomach contents and aspiration during surgery or procedures requiring anesthesia; tell your care team you are taking this medication before any procedure. Do not use during pregnancy or breastfeeding. Do not use with another GLP-1 medication. The most common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue.
Semaglutide is self-administered as a weekly subcutaneous injection. Follow your provider's and pharmacy's instructions exactly; dosing from a vial and syringe carries a risk of dosing error, so confirm your dose in the correct units. Do not change your dose or stop without discussing with your provider. This information is not comprehensive.
Tirzepatide is the active ingredient in the FDA-approved products Mounjaro and Zepbound. Compounded tirzepatide is not FDA-approved and has not undergone the clinical studies required for FDA-approved products. The FDA-approved brand products carry a boxed warning for the risk of thyroid C-cell tumors, including MTC; the same risk should be assumed for compounded tirzepatide. Do not use if you or a family member has had MTC or MEN 2, or if you have had a serious allergic reaction to tirzepatide.
Before use, tell your provider about all medical conditions and all medicines you take, especially insulin or sulfonylureas. Possible serious risks include pancreatitis, gallbladder problems, kidney problems, serious allergic reactions, low blood sugar, vision changes, gastroparesis, and depression or thoughts of suicide. There is a risk of retained stomach contents and aspiration during anesthesia; tell your care team before any procedure. Tirzepatide may reduce the effectiveness of oral birth control; discuss alternatives with your provider. Do not use during pregnancy or breastfeeding. Do not use with another GLP-1 medication. The most common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, and fatigue.
Tirzepatide is self-administered as a weekly subcutaneous injection. Follow your provider's and pharmacy's instructions exactly; dosing from a vial and syringe carries a risk of dosing error, so confirm your dose in the correct units. Do not change your dose or stop without discussing with your provider. This information is not comprehensive.
Contact: support@ozarihealth.com
© Ozari LLC